跳至主要内容
临床试验/NCT03995004
NCT03995004暂停1 期

The Effect of Melatonin on Postoperative Pain Reduction After Orthognathic Surgery

The University of Hong Kong1 个研究点 分布在 1 个国家目标入组 87 人开始时间: 2022年10月最近更新:
适应症
干预措施
相关药物

试验速览

阶段
1 期
状态
暂停
入组人数
87
试验地点
1
主要终点
Total analgesic consumption

研究概览

简要总结

Orthognathic surgery is a procedure performed to correct dentofacial deformities. It involves osteotomy at the facial skeleton. Considerable pain is expected in the early recovery period.

Melatonin is a hormone that is produced naturally by the body. Synthetic Melatonin is available over the counter for the management of sleeping disorder and jetlag. Clinically, Melatonin can also be used to reduce pain and analgesic consumption in patients undergoing surgery.

Dexamethasone is a type of steroid. It can suppress the inflammatory response. It is an anti-inflammatory, anti-allergic drug. It is commonly used in head and neck and oral surgery for its anti-inflammatory effect to reduce swelling.

This study aims evaluate the efficacy of oral melatonin in the pain reduction following orthognathic surgery.

This is a double-blinded randomized controlled trial. We will recruit 87 patients who are scheduled for double-jaw orthognathic surgery to participate in this three-year study. The study lasts for 2 weeks. Participant will be randomly allocated by computer to one of the three groups. (1) Group D will receive dexamethasone only; (2) Group M will receive melatonin only; and (3) Group DM both melatonin and dexamethasone.

Postoperative pain level and perioperative plasma levels of inflammatory markers and anti-oxidizing enzymes will be recorded and compared among the study groups.

详细描述

Melatonin (N-acetyl-5-methoxytryptamine) is a neurohormone that is endogenously produced and secreted by the pineal gland in the brain following a circadian rhythm, with a plasma concentration highest at night and lowest during the day.

The normal physiological roles of melatonin in the human body are to regulate diurnal rhythm, sleep, mood, immunity, reproduction, intestinal motility, and metabolism. Oral supplemental melatonin has been used in the management of jetlag and other sleep disorders. Recently, melatonin's analgesic, antioxidative, and neuroprotective properties have been highlighted in a number of animal models and a few human trials, although the exact cellular mechanism is still not yet clearly established. In surgical human trials, some conflicting data have been presented regarding the analgesic properties of exogenous melatonin supplement. Whilst the large proportion of studies showed that perioperative administration of melatonin yielded significantly positive effects in the reduction of postsurgical pain, and the reduction of overall morphine consumption, others demonstrated the opposite with no significant effects in pain experience. The reason for this could be related to the dosage, route of administration, and/or time of administration. To date, there is still no consensus on a standardized dosing regimen for melatonin. In non-surgical trials, melatonin has shown promising benefits in many degenerative diseases and conditions related to chronic inflammation and oxidative stress. Amongst many, the reported positive effects of melatonin ranged from the reduction of radiation dermatitis, control of signs and symptoms of ulcerative colitis, management of chronic retinopathy, and reduction of lung oxidative stress in chronic obstructive pulmonary disease patients.

Hypothesis:

Melatonin can significantly reduce postoperative pain after orthognathic surgery. Antioxidative enzyme activity and level will be elevated and the level of inflammatory markers are reduced. Melatonin has a synergistic effect with dexamethasone.

This is a double-blinded randomized controlled trial. We will recruit 87 patients who are scheduled for double-jaw orthognathic surgery to participate in this three-year study. The study lasts for 2 weeks. Participant will be randomly allocated by computer to one of the three groups. (1) Group D will receive dexamethasone only; (2) Group M will receive melatonin only; and (3) Group DM both melatonin and dexamethasone.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

盲法说明

Identical capsules for melatonin and placebo Clear fluid of the same volume for IV dexamethasone vs normal saline

入排标准

年龄范围
18 Years 至 60 Years(Adult)
性别
All
接受健康志愿者

入选标准

  • ASA Class I
  • Age between 18 - 60 inclusive

排除标准

  • Pregnancy
  • Any pre-existing systemic condition
  • Previous history of orthognathic surgery
  • Adverse reaction or allergic to oral melatonin
  • Need for distraction osteogenesis
  • Patient with chronic pain
  • Patients with known psychological disorders
  • Currently taking oral steroid or anti-inflammatory medication or any analgesic

研究组 & 干预措施

Dexa_Melatonin

Experimental

Oral Melatonin 10mg at night time one day before the surgery and on the surgical day, and continued at bedtime on the surgical day, post-surgery day 1 and day 2.

IV Dexamethasone 4mg/1mL on induction and continued q12h for 4 more doses

干预措施: Melatonin (Drug)

Melatonin

Experimental

Oral Melatonin 10mg at night time one day before the surgery and on the surgical day, and continued at bedtime on the surgical day, post-surgery day 1 and day 2.

IV Normal Saline (1mL) on induction and continued q12h for 4 more doses.

干预措施: Melatonin (Drug)

Dexamethasone

Active Comparator

Placebo capsules at night time one day before the surgery and on the surgical day, and continued at bedtime on the surgical day, post-surgery day 1 and day 2.

IV Dexamethasone 4mg/1mL on induction and continued q12h for 4 more doses

干预措施: Dexamethasone Sodium Sulphate 4mg/1mL (Drug)

Dexa_Melatonin

Experimental

Oral Melatonin 10mg at night time one day before the surgery and on the surgical day, and continued at bedtime on the surgical day, post-surgery day 1 and day 2.

IV Dexamethasone 4mg/1mL on induction and continued q12h for 4 more doses

干预措施: Dexamethasone Sodium Sulphate 4mg/1mL (Drug)

结局指标

主要结局

Total analgesic consumption

时间窗: 14 days

Total amount of postoperative analgesic consumed

Subjective pain perception

时间窗: 14 days

Self-reported pain level by numerical rating scale

次要结局

  • Plasma levels and activities of antioxidative enzymes(16 days)
  • Time to first analgesic(1 day)
  • Plasma levels of inflammatory markers(16 days)
  • Plasma levels of hydrogen peroxide(16 days)
  • Plasma levels of melatonin(16 days)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验